SYNTHOS RESEARCH

Ares Management ARES

Financial Services · Asset Management · Synthos Deep Dive · 2026-07-03

$116.90
Hold
Risk 7Growth 7Exponential 5Fair value $176 $96–$240

At a glance

VerdictHold — systematic Synthos tier
Price (2026-07-02)$116.90 · market cap ~$38.4B
Synthos scores (0–10)Downside Risk 7 · Growth Quality 7 · Exponential Potential 5
Synthos fair value (base case)~$176+50% · full range $96 (bear) – $240 (bull)
Street consensus$171.13 (high $215 / low $140; 1 Strong Buy · 16 Buy · 5 Hold · 0 Sell) — context, not our anchor
Valuation52× trailing GAAP EPS (misleading for an alt-manager) · ~23× FY26E · ~16× FY27E adjusted EPS · EV/EBITDA 21× · P/B 6.5×
Exponential Potential5/10 · Moderate — ~20% forward adjusted-EPS CAGR and a huge private-credit TAM, but this is a cyclical fee compounder, not a fast multibagger
TechnicalsDowntrend — $116.90, −39% off 52-wk high, below 50-DMA ($123) and 200-DMA ($138), RSI 31 (near oversold), −33% 12-mo (SPY +21%)
ConvictionLow / Split — only 5 KB claims: one bull (Business Breakdowns, conv 80) and one live bear (Jordi Visser, conv 78: "private credit is cracking")
Position sizingTactical satellite, ~1–3% — a mean-reversion / value tilt, not a core holding
Next catalyst2026-07-31 Q2'26 earnings (Street EPS $1.35, revenue ~$1.33B)
Single biggest riskA private-credit / direct-lending credit cycle — widening junk spreads, defaults, and slowing fundraising would hit fees, carry, and the balance sheet at once

One-line thesis. Ares is a top-tier alternative-asset manager ($644B AUM, growing fee-related earnings) whose stock has been cut ~40% on fears that the $1.7T private-credit boom is turning — leaving it cheap on forward adjusted earnings (~16× FY27E) but squarely a bet on the credit cycle, which is exactly why our two expert voices split bull-vs-bear and we size it small.

◆ Synthos call — Hold ARES is a solid business largely reflected at ~$176 — fine to keep, no reason to chase; it gets interesting again below ~$150.
Downside Risk (lower = safer)
7/10 · High
5.3× net-debt/EBITDA, beta 1.52, −41% drawdown, and a live private-credit-cycle bear thesis on record.
Growth Quality
7/10 · High
~20% forward adjusted-EPS CAGR on recurring fee earnings; $644B AUM compounding; but leverage-aided ROE.
Exponential Potential
5/10 · Moderate
Big, growing private-credit TAM and FRE compounding — but cyclical, not a fast multibagger; $38B cap is mid-size.
⚖ Reverse-DCF cross-check Market-implied growth ≈ 30%/yr To justify today’s $117, earnings would have to compound roughly 30% a year for 10 years (9% discount rate). Analysts forecast ~16%/yr, so the market is pricing in MORE than what the Street expects.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

Ares is a money manager for the wealthy and for big institutions (pensions, insurers). It doesn't manage plain stock funds — it specializes in "alternatives": lending directly to mid-size companies (private credit), private equity, and real estate. It earns steady management fees on the $644 billion it oversees, plus a cut of the profits when its funds do well.

The stock is down about 40% from last year's high. Two things are pulling on it. On paper the "P/E" looks scary-high (52×), but that number is misleading for this kind of company — on the earnings measure Wall Street actually uses, it trades around 16 times next-year profits, which is not expensive for a business growing ~20% a year. The worry is the other side: Ares makes a lot of its money lending to companies, and if the economy sours and those loans go bad, its fees, its profit-share, and its own borrowed-up balance sheet all get hit at the same time.

Our verdict is Buy — Tactical: cheap enough and beaten-down enough to be worth a small bet on a bounce, but not a "sleep well at night" core holding.

Here's what our three scores mean in everyday terms:

The one big worry: a private-credit downturn. One of the two experts we track is on record right now warning that this corner of finance is "cracking."


Price & moving averages 12 months · 50 & 200-day averages · 52-week range

89117145173200Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2652w hi $193200-DMA 13850-DMA 123Price 11752w lo $97

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

87116145174203Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2620-day avg 123Price 117

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

705030Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26RSI 44.7

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 45.

MACD 12 / 26 / 9 · trend & momentum

0Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26signal -1.8MACD -3.4

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago

496988108128Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26S&P 500 120XLF (sector) 106ARES 66

Solid = ARES · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

0371013$3BFY22EPS $3$3BFY23EPS $2$4BFY24EPS $4$5BFY25EPS $5$6BFY26EEPS $6$7BFY27EEPS $7$8BFY28EEPS $9$12BFY29EEPS $9

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$116.90
Market cap$38B
P/E trailing
P/E FY26E / FY27E19× / 16×
EV / Sales8.1×
EV / EBITDA21.1×
Gross margin70.7%
Net margin9.9%
Dividend yield4.23%
Beta1.516
52-wk range$97 – $193
RSI(14)31
50 / 200-DMA$123 / $138
12-mo return+-33% (SPY +21%)
Street target$171 ($140–$215)
Analyst grades16 Buy · 5 Hold · 0 Sell
FMP ratingC
Next earnings2026-08-05

What the experts actually said 5 traceable claims on ARES · showing the highest-conviction voices

“Top-tier BDCs are now institutional-quality products investing alongside vetted private funds—the old einhorn-era 'nefarious scheme' view is outdated.”
Business Breakdownsbullishconviction 80n/abusiness_breakdowns-Haj78lrOlbI:9fbc1a8270
“Private equity and the 1.7T private credit market are cracking; BDCs and PE names have fallen violently, signaling widening junk spreads.”
Jordi Visser Aibearishconviction 782025-10-12jordi_visser_ai-urLT0eDzoaw:abb62440df

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

Ares Management (NYSE: ARES) is a Los Angeles–based global alternative asset manager, founded 1997, IPO'd 2014. It runs money across four engines: Tradable Credit (liquid non-investment-grade corporate credit — CLOs, loans, pooled and separately managed accounts), Direct Lending (private credit to small- and mid-sized companies — its flagship franchise), Private Equity (control/co-control positions in under-capitalized businesses), and Real Estate (development, repositioning, and specialty financing). Per the Q1'26 release, total AUM is $644.3B, Fee-Paying AUM $399.6B, available "dry powder" capital $158.1B. Fiscal year ends December 31. CEO/co-founder Michael Arougheti.

Why the GAAP income statement looks weird. Ares consolidates many of the funds it manages, so its GAAP revenue ($6.47B FY25) and GAAP EPS ($1.96) are distorted by fund-level items and large minority interest. The numbers management, analysts, and this note actually track are the non-GAAP ones: Fee Related Earnings (FRE) and Realized Income (RI). Q1'26: FRE $464.4M, RI $502.7M, after-tax RI $1.24/share. Read the "EPS" in the estimates table below as adjusted EPS, not GAAP.

Revenue mix (FY2025 product segmentation, from filings):

Geographic segmentation is not broken out in the FMP feed (seg_geo empty); the firm operates across the US, Europe, and Asia.

2. The expert thesis — a genuine bull-vs-bear split (traceable)

Honest coverage note: the Synthos KB has only 5 claims on ARES, and they do not agree. This is not a high-conviction, broad-panel name like our flagship compounders. The verdict here is primarily fundamentals- and quant-driven, with the two named voices used as guardrails, not as an anchor. Both sides are on record:

Honest composite. Net-bullish voices = 1, but the signed picture is essentially a draw: a structural bull vs. a recent, credible cyclical bear. We do not manufacture conviction from a split panel. The tie-breaker is the data — cheap forward multiple + recurring fee base (bull) vs. leverage + credit-cycle timing (bear) — which is why this lands as a small, tactical call rather than a core one.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score0–10The read
Downside Risk (lower = safer)7 · ElevatedNet-debt/EBITDA 5.3×, debt/equity 3.5×, beta 1.52, a −41% max drawdown, and a live private-credit-cycle bear thesis. The dividend ($4.94) is not covered by GAAP EPS — it's paid from adjusted cash earnings, so a fee/realization air-pocket pressures it.
Growth Quality7 · Good~20% forward adjusted-EPS CAGR, $644B AUM compounding with $158B dry powder, majority-recurring management fees, ROE 14.5%. Docked because the ROE is leverage-aided and carry is cyclical.
Exponential Potential5 · ModeratePrivate-credit TAM is large and still growing and FRE compounds, but this is a cyclical fee machine, not an accelerating secular multibagger; at $38B cap it's mid-size with room, but the second derivative is cycle-dependent.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. All EPS figures are adjusted (After-tax RI basis), consistent with the estimate feed.

CaseKey assumptionsFair value
BullPrivate-credit fears prove overblown; fundraising re-accelerates, carry realizations resume, AUM compounds mid-teens. FY27E adj EPS beats toward ~$8.0; multiple re-rates to ~30× as the cycle fear lifts.~$240 (+105%)
Base (our anchor)Estimates roughly hit — FY26E adj EPS ~$6.00, FY27E ~$7.37; a durable ~20% fee compounder earns a ~24× forward multiple as spreads stabilize.~$176 (+50%)
BearVisser is right — the credit cycle turns, defaults rise, fundraising stalls, carry evaporates, and the leverage bites. FY26E adj EPS misses to ~$6.0 and the multiple de-rates to ~16×; the stock revisits the 52-wk low.~$96 (−18%)

Synthos fair value = the base case, ~$176 (+50%), with the full $96–$240 span as the honest range — a wide range by design, because this is a cyclical whose outcome hinges on one macro variable (the credit cycle). This anchor sits essentially in line with the Street's $171 consensus. Note the asymmetry: the upside is large if the cycle holds, but the bear is a genuine −18% (and the drawdown to date shows the downside is real). This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). ARES is a cyclical fee compounder, not a secular exponential:

Exponential Potential: Moderate (5). Own it for a cyclical-recovery + fee-compounding tilt, not for a fast, all-weather multibagger. The honest framing is why ARES is a satellite, not a core.

5. Financials (real numbers — FMP annual/quarterly; note GAAP vs. adjusted)

6. Valuation — cheap on the right metric, not the wrong one

Do not use the 52× trailing GAAP P/E — for a consolidating alt-manager it's meaningless. On the measure the Street and management use (adjusted / After-tax RI EPS), the forward multiples are ~23× FY26E ($6.00) → ~16× FY27E ($7.37) → ~13× FY28E ($8.70) — i.e. the multiple compresses quickly if estimates hit, and ~16× FY27 is reasonable-to-cheap for a ~20% fee compounder. EV/EBITDA is 21×, P/B 6.5×, and the dividend yield is ~4.2% ($4.94). The FMP letter rating is C (score 2/10) — but that model is anchored on GAAP P/E, P/B, and debt/equity, all of which read punitively for a levered alt-manager; it materially understates the fee-earnings quality. Street targets (context): consensus $171.13, high $215, low $140, median $164 — our $176 base sits right on top of consensus. The honest read: not expensive on forward adjusted earnings; the entire debate is whether those earnings hold through the credit cycle — a macro call, not a multiple call.

7. Technicals (from the tech block)

8. Moat & competitive position

Ares' moat is scale, track record, and fund-raising machinery in a category (private credit / direct lending) that is still taking share from retreating banks. Scaled incumbents with long performance histories and deep LP relationships raise capital more cheaply and win the largest deals — a real barrier for sub-scale entrants. The Business Breakdowns bull (business_breakdowns-Haj78lrOlbI:9fbc1a8270) is precisely this: private credit has become an institutional-quality product, and the toll-collectors benefit. The moat's limit: it is a cyclical moat — durable in expansions, tested in credit contractions, when defaults, mark-downs, and slowing fundraising hit fees and carry simultaneously (the Visser bear).

Peer set (from the feed, market cap): Apollo Global $68B (the closest large alt-manager comp), Blue Owl Capital $14B (direct-lending pure-play), Morgan Stanley $337B, State Street $47B, Raymond James $32B, SoFi $23B, Brown & Brown $24B, Huntington Bancshares $36B. Against Apollo and Blue Owl — the truest comps — Ares is the mid-cap alt-credit specialist; its ~40% drawdown has been broadly shared across the private-credit cohort, which is the market voting on the Visser thesis.

9. Management, capital allocation & guidance

10. Catalysts & what to watch

Thesis tripwires (what would change the call): rising non-accruals / credit marks in the lending book; two consecutive quarters of net outflows; FRE growth stalling; or the dividend outrunning after-tax RI. Any of these flips this from Tactical toward Avoid.

11. Key risks

12. Verdict, position sizing & monitoring

Buy — Tactical. ARES is a genuinely good business (scaled alt-credit manager, $644B AUM, growing recurring fees) that has been cut ~40% and now trades cheap on the right metric (~16× FY27E adjusted EPS, ~4.2% yield) while sitting oversold (RSI 31, near a base). That is a real mean-reversion / value setup, and the +50% to our $176 base (in line with the $171 Street) is attractive if the credit cycle holds. But we will not dress this up as a core conviction call: the KB is a draw (one structural bull, one recent credible bear), the balance sheet is levered 5.3×, and the whole thesis rides on one macro variable. That combination is a small tactical position, not a flagship core weight.


Provenance & disclosures